# Dara-BCD for Rare MGRS

> **NCT06771180** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Monoclonal Gammopathy of Renal Significance (MGRS)

## Interventions

- **DRUG:** Dara-CyBorD

## Key facts

- **NCT ID:** NCT06771180
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-15
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06771180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06771180, "Dara-BCD for Rare MGRS". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT06771180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*